Skip to main content
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

Roundup: FDA Approves Lilly’s Olumiant, AbbVie’s Juvmo, Mirum & Incyte’s Atebrioz

Summary by pharmexec.com
FDA this week cleared three new treatments: Lilly's Olumiant for adolescent alopecia areata, AbbVie's Juvmo for Parkinson's disease, and Mirum and Incyte's Atebrioz for the rare bone disorder FOP.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

pharmexec.com broke the news on Monday, September 28, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal